Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$4.30 USD
-0.66 (-13.23%)
Updated May 21, 2024 03:59 PM ET
After-Market: $4.29 -0.01 (-0.12%) 5:44 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GLUE 4.30 -0.66(-13.23%)
Will GLUE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GLUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GLUE
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
GLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
Other News for GLUE
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
Monte Rosa Therapeutics presents data at DDW 2024 on MRT-6160
Monte Rosa Therapeutics prices $100M stock and warrants offering
SPIR, ADTH and AWIN among pre-market losers
12 Health Care Stocks Moving In Thursday's Pre-Market Session